Our News

All the latest company news, views and insight from the Beckley Psytech team.

The Science Explained

Wearable technology can revolutionise our clinical research

Becky Hutchinson, commercial director at Beckley Psytech

In The News

News article on the appointment of Andy Page as Beckley Psytech’s new Chief Operating Officer.

Company Announcements

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer 

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer with immediate effect.

Image: Adenanthera colubrina flowers and seed pods. Source: Wikimedia commons.
The Science Explained

Understanding 5-MeO-DMT: Historical use

Part One: Plants

In The News

Article on Beckley Psytech receiving UK Clinical Trial Authorisation to explore the effects of psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), featuring a quote from Dr Fiona Dunbar, Chief Medical Advisor.

Company Announcements

Beckley Psytech receives approval for clinical trial using psychedelic agent to treat severe headach...

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to e... Read More

In The News

Article on the prospects for the psychedelic drugs market with comments from Beckley Psytech CEO Cosmo Feilding-Mellen following the news of the company’s latest £14m funding round.

In The News

News article on the £14m funding round to finance a drug development pipeline for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding-Mellen and investor James Bailey from Bail Capital. 

In The News

News article on the successful latest funding round to finance Beckley’s lead development programme on synthetic 5-MeO-DMT. 

In The News

Exclusive news article on the $18.6m funding round, featuring Beckley Psytech’s pitch deck and comments from CEO Cosmo Feilding-Mellen.